〜AIM is the first Japanese company to establish a research partnership in the field of endoscopic AI〜
AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, has announced a joint research agreement with The Chinese University of Hong Kong (hereinafter CUHK), one of the world’s top research universities, on November 1, 2022. AIM is the first Japanese company to sign a joint research agreement with CUHK in the field of endoscopic AI.
■Content and Objective of the Joint Research
AIM is now working toward receiving regulatory approval in Japan for its endoscopic AI product designed to identify early-stage gastric cancer. Its collaboration with CUHK, AIM will facilitate joint research that investigates the implementation of Japanese AI and accelerates market development in Hong Kong and other Asian countries.
Founded in 1963, CUHK is one of the world’s top comprehensive research universities with a mission to connect China and the West. CUHK focuses on future-oriented research from a global perspective. CUHK is ranked 12th in Asia and 38th in the world by the QS World University Rankings*.
By collaborating with one of Asia's leading research universities in the field of gastrointestinal care, AIM will explore the potential of using Japanese endoscopic AI for clinical practice in Hong Kong.
■About AI Medical Service Inc.
AI Medical Service (AIM) is a Tokyo-based med-tech company established with the mission to “Save Lives All Over the World.” Japan leads the world in endoscopic diagnosis and treatment, providing firms and researchers with access to large amounts of high-quality data. AIM is the leading player in the field of endoscopic AI, engaging in joint research with more than 100 medical institutions. By bringing endoscopic AI to the real-world clinical setting as soon as possible, AIM aims to reduce the number of missed cancer diagnoses and save lives around the world.
■About CEO of AI Medical Service Inc., Dr. Tada
Tomohiro TADA, M.D., Ph.D.
Dr. Tomohiro TADA is the CEO of AI Medical Service Inc., the chairperson of Tada Tomohiro The Institute of Gastroenterology & Proctology, and Visiting Lecturer, Department of Surgical Oncology, Graduate School of Medicine, the University of Tokyo Hospital.
Dr. TADA received his M.D. of school of medicine in 1996 and Ph.D. of department of surgery in 2005 from the University of Tokyo. He trained in Colorectal Surgery at the University of Tokyo Hospital.
■Related Press Release
・Jan. 17, 2023 “AI Medical Service Inc. Relocates its Singapore Office to the NUHS Center for Innovation in Healthcare (CIH), strengthening ties with National University Hospital”
・Jan. 1, 2023 “AI Medical Service Inc. Establishes US Second Base〜Fortifying a framework for business expansion in the U.S.〜”
・Jul. 11, 2022 “AIM Establishes local subsidiary in Singapore 〜Accelerating the overseas expansion of “Endoscopic AI” by establishing a second overseas branch〜”
・Jan. 19, 2022 “AIM Establishes U.S. subsidiary in Silicon Valley as a first overseas branch”
・Apr. 27, 2021 “AIM and Singapore’s National University Hospital Sign Joint Research Agreement on Endoscopic AI”
Company Profile ―――――――――――――――――――――――――――――
Company： AI Medical Service Inc.
Address： Hareza Tower 11F, 1-18-1 Higashiikebukuro, Toshima-ku, Tokyo 170-0013, Japan
CEO： Tomohiro Tada
Founding： September 1, 2017
Business： Development of Endoscopic AI
Feel free to contact us using the form below regarding joint research,
media coverage, business partnerships, or related opportunities.